ERBB2 and breast cancer: Since TAM infiltration has already been associated to immunosuppression and poor prognosis in HER2+ BC patients (21, 22, 96), and given that myeloid cells appear to be directly modulated by anti-HER2 antibody challenge in our models, we looked further into the myeloid subset of immune cells.